Omega Diagnostics

United Kingdom
Alva, Scotland, United Kingdom, FK12 5DQ

Company profile

Omega Diagnostics company profile

Omega Diagnostics Group PLC, through its subsidiaries, engages in the manufacture, development, and distribution of medical diagnostic products. The company operates in three segments: Allergy and Autoimmune, Food Intolerance, and Infectious Disease. The Allergy and Autoimmune segment engages in the research, development, production, and marketing of in vitro allergy and autoimmune tests that are used by doctors to diagnose patients with allergies and autoimmune diseases. This segment’s principal products include Allergozyme, Allergodip, and Genesis Elisa. The Food Intolerance segment engages in the research, development, and production of kits that are used in the detection of immune reactions to food. It also provides clinical analysis to the general public, clinics, and health professionals, as well as supplies consumer food detective test. This segment’s principal products include Genarrayt microarray, Food Detective, and Foodprint service. The Infectious Disease segment engages in the research, development, production, and marketing of kits that are used in the diagnosis of infectious diseases, such as syphilis, tuberculosis, dengue fever, Chagas disease, and malaria. Its principal products comprise Immutrep Syphilis, Micropath Bacterial tests, and Dengue Elisa. The company offers its diagnostic kits and systems to hospitals, blood banks, clinics, and laboratories through distributors in approximately 100 countries worldwide. Omega Diagnostics Group PLC was founded in 1987 and is headquartered in Alva, the United Kingdom.

Business identity

Contact email
[email protected]
Phone number
+44 1259 763030
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
1987-01-01, Year

Headquarters

Postal code
FK12 5DQ
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
5
Total equity funding
$12.8M
Last funding
Post IPO Equity / $6.8M / 2022-02-11
Last equity funding
Post IPO Equity / $6.8M
Investors
3
Lead investors
1
Founders
1
Articles
42
Exited on
2010-12-21

Founders and investors

Founders

Andrew Shepherd

Lead investors

Mobeus Equity Partners

Investors

Hygea VCTMobeus Equity PartnersParkwalk Advisors